세계의 바이러스성 간염 시장 보고서(2025년)

Viral hepatitis encompasses a group of infectious diseases resulting from various viruses (hepatitis A, B, C, D, and E), primarily affecting the liver. The symptoms may vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.

The primary types of viral hepatitis diseases include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a potentially life-threatening liver ailment caused by the hepatitis A virus. Diagnosis is typically achieved through liver biopsy, blood tests, imaging tests, and other diagnostic methods. Treatment options involve antiviral drugs, surgery, vaccines, immune modulator drugs, and others. These treatments can be administered through various routes, including oral and parenteral, and are commonly offered in hospitals, specialty clinics, homecare settings, and other relevant healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The viral hepatitis market research report is one of a series of new reports from The Business Research Company that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.77 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.71 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.

The forecast of 4.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of direct-acting antiviral drugs and liver elastography devices sourced from Egypt and France, thereby limiting treatment affordability and elevating hepatology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of hepatitis is expected to drive the growth of the viral hepatitis market in the coming years. Hepatitis refers to a liver infection caused by various infectious viruses and non-infectious substances, leading to several health complications. Hepatitis A, B, C, D, and E are some of the viruses responsible for viral hepatitis, which causes liver inflammation and damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a government health agency based in Sweden, reported 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from the 16,187 cases recorded in 2021. Furthermore, the total number of cases in 2022, which amounted to 28,420, represented a crude rate of 8.5 cases per 100,000 people. Therefore, the growing prevalence of hepatitis will fuel the expansion of the viral hepatitis market.

The increasing volume of research and development (R&D) endeavors is expected to serve as a powerful growth driver for the viral hepatitis market. Research and development initiatives focused on viral hepatitis encompass a wide spectrum of activities, including the development of vaccines, antiviral medications, diagnostic tests, epidemiological studies, public health interventions, genomic research, prevention strategies, global health campaigns, clinical trials, and investigations into co-infections. The upsurge in R&D activities not only fosters innovation in treatment approaches but also expands the array of options for diagnosis and prevention. This, in turn, leads to a higher number of clinical trials, stronger global health initiatives, and heightened competition among pharmaceutical companies. For instance, in November 2022, researchers in Melbourne secured funding of $1.7 million for the next five years through the mRNA Victoria Activation Program. This funding is set to advance their pioneering work in the quest for a cure for hepatitis B virus infection. Consequently, the escalation in the number of research and development activities is a driving force behind the growth of the viral hepatitis market.

Prominent companies active in the viral hepatitis market are dedicated to advancing the development of new drugs to reinforce their position within the market. The pursuit of drug development and innovation serves to enrich scientific understanding by shedding light on disease mechanisms, thus expediting the creation of novel treatments. For instance, in November 2022, Gilead Sciences Inc., a biopharmaceutical company based in the United States, disclosed the FDA's granting of the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. These tablets are designed for once-daily administration to address chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. The approval for Vemlidy's utilization in this specific group of pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.

In November 2023, GSK plc, a pharmaceuticals company based in the U.K., acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the acquisition of the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to enhance its portfolio and reinforce its position in the chronic hepatitis B treatment space by adding a new and potentially valuable therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, is known for developing treatments for infectious diseases, including chronic hepatitis B.

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Hepatitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral hepatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral hepatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viral hepatitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
• 2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
• 3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A
• 2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
• 3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
• 4) By Other Disease Types: Hepatitis D; Hepatitis E
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Co; F Hoffmann-La Roche AG; Merck & Co.; AbbVie Inc.; Novartis AG; Sanofi SA; Bristol-Myers Squibb; Astra Zeneca Pharmaceuticals LP; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Co. Ltd.; Hetero Drugs Ltd.; Eisai Co. Ltd.; Boehringer Ingelheim Group; Sun Pharmaceutical Industries Ltd.; Lupin Limited; Dr. Reddy's Laboratories; Zydus Lifescience Ltd.; Glenmark Pharmaceuticals Ltd.; Cipla Ltd.; Torrent Pharmaceuticals Ltd.; Otsuka Pharmaceutical Co. Ltd.; Wockhardt Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral Hepatitis Market Characteristics

3. Viral Hepatitis Market Trends And Strategies

4. Viral Hepatitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Viral Hepatitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral Hepatitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral Hepatitis Market Growth Rate Analysis
• 5.4. Global Viral Hepatitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral Hepatitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral Hepatitis Total Addressable Market (TAM)

6. Viral Hepatitis Market Segmentation

• 6.1. Global Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Other Disease Types
• 6.2. Global Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Biopsy
• Blood Tests
• Imaging Tests
• Other Diagnosis
• 6.3. Global Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Drugs
• Surgery
• Vaccine
• Immune Modulator Drugs
• Other Treatments
• 6.4. Global Viral Hepatitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.5. Global Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis A
• Chronic Hepatitis A
• 6.7. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis B
• Chronic Hepatitis B
• Hepatitis B Carrier
• 6.8. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis C
• Chronic Hepatitis C
• 6.9. Global Viral Hepatitis Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis D
• Hepatitis E

7. Viral Hepatitis Market Regional And Country Analysis

• 7.1. Global Viral Hepatitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral Hepatitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Hepatitis Market

• 8.1. Asia-Pacific Viral Hepatitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Hepatitis Market

• 9.1. China Viral Hepatitis Market Overview
• 9.2. China Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Hepatitis Market

• 10.1. India Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Hepatitis Market

• 11.1. Japan Viral Hepatitis Market Overview
• 11.2. Japan Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Hepatitis Market

• 12.1. Australia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Hepatitis Market

• 13.1. Indonesia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Hepatitis Market

• 14.1. South Korea Viral Hepatitis Market Overview
• 14.2. South Korea Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Hepatitis Market

• 15.1. Western Europe Viral Hepatitis Market Overview
• 15.2. Western Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Hepatitis Market

• 16.1. UK Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Hepatitis Market

• 17.1. Germany Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Hepatitis Market

• 18.1. France Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Hepatitis Market

• 19.1. Italy Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Hepatitis Market

• 20.1. Spain Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Hepatitis Market

• 21.1. Eastern Europe Viral Hepatitis Market Overview
• 21.2. Eastern Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Hepatitis Market

• 22.1. Russia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Hepatitis Market

• 23.1. North America Viral Hepatitis Market Overview
• 23.2. North America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Hepatitis Market

• 24.1. USA Viral Hepatitis Market Overview
• 24.2. USA Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Hepatitis Market

• 25.1. Canada Viral Hepatitis Market Overview
• 25.2. Canada Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Hepatitis Market

• 26.1. South America Viral Hepatitis Market Overview
• 26.2. South America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Hepatitis Market

• 27.1. Brazil Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Hepatitis Market

• 28.1. Middle East Viral Hepatitis Market Overview
• 28.2. Middle East Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Hepatitis Market

• 29.1. Africa Viral Hepatitis Market Overview
• 29.2. Africa Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Hepatitis Market Competitive Landscape And Company Profiles

• 30.1. Viral Hepatitis Market Competitive Landscape
• 30.2. Viral Hepatitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral Hepatitis Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb
• 31.4. Astra Zeneca Pharmaceuticals LP
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Gilead Sciences Inc.
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Co. Ltd.
• 31.12. Hetero Drugs Ltd.
• 31.13. Eisai Co. Ltd.
• 31.14. Boehringer Ingelheim Group
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Viral Hepatitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Hepatitis Market

34. Recent Developments In The Viral Hepatitis Market

35. Viral Hepatitis Market High Potential Countries, Segments and Strategies

• 35.1 Viral Hepatitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral Hepatitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral Hepatitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer